KZR KEZAR LIFE SCIENCES INC Other Situations 8-K Filing 2023 - Clinical Trial Update Kezar Life Sciences, Inc. provides an update on its Phase 1 clinical trial of KZR-261, stating that the trial has not reached a maximum tolerated dose and expects to report safety and dose escalation data in 2024.Get access to all SEC 8-K filings of the KEZAR LIFE SCIENCES INC